<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02753088</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-063-1</org_study_id>
    <nct_id>NCT02753088</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of BCD-063 and Copaxone-Teva in Patients With Relapsing-Remitting Multiple Sclerosis</brief_title>
  <official_title>International, Multicentre, Double-blind, Placebo-controlled, Comparative, Randomized Study to Compare Efficacy and Safety of the Generic Drug BCD-063 (CJSC &quot;BIOCAD&quot;, Russia) and Copaxone®-Teva (&quot;Teva Pharmaceutical Industries Limited&quot;, Israel) in Patients With Relapsing-remitting Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the clinical study of the medicinal product for medical use: to compare&#xD;
      efficacy and safety of the generic drug BCD-063 and Copaxone®-Teva in patients with&#xD;
      relapsing-remitting multiple sclerosis.&#xD;
&#xD;
      Period of the clinical study of the medicinal product for medical use: from June 10, 2013 to&#xD;
      March 23, 2016.&#xD;
&#xD;
      Number of patients, involved into the study of the medicinal product for medical use: 158&#xD;
      patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative Unique Activity lesions</measure>
    <time_frame>48 weeks</time_frame>
    <description>Cumulative Unique Activity (CUA) detected by MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Annual relapse rate</measure>
    <time_frame>48 weeks</time_frame>
    <description>Relapse per patient per year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients without relapses</measure>
    <time_frame>48 weeks</time_frame>
    <description>Proportion of patients without confirming relapses with magnetic resonance imaging (MRI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing in volume of hypointense T1 lesions</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changing in volume of T2 lesions</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of new or extended lesions in T2 regimen</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients proportion without lesions</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1 lesions amount</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale dynamics</measure>
    <time_frame>Week 24, Week 48</time_frame>
    <description>Expanded Disability Status Scale (EDSS) scale count at 24th and 48th week, comparing count at week 24 to week 48 for each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression on Multiple Sclerosis Functional Composite scale comparing to the baseline</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of relapse</measure>
    <time_frame>48 weeks</time_frame>
    <description>Relative Risk Ratio for relapse in each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time till the first relapse</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite scale dynamics</measure>
    <time_frame>24, 48 weeks</time_frame>
    <description>Multiple Sclerosis Functional Composite (MSFC) scale count at 24th and 48th week, comparing count at week 24 to week 48 for each group</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">158</enrollment>
  <condition>Relapsing-remitting Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>BCD-063 (glatiramer acetate)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of glatiramer acetate BCD-063 subcutaneously every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Copaxone-Teva (glatiramer acetate)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous injection of glatiramer acetate Copaxone-Teva subcutaneously every day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subcutaneous injection of mannitol 40 mg, water for injections till 1 ml, every day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCD-063</intervention_name>
    <arm_group_label>BCD-063 (glatiramer acetate)</arm_group_label>
    <other_name>glatiramer acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Copaxone-Teva</intervention_name>
    <arm_group_label>Copaxone-Teva (glatiramer acetate)</arm_group_label>
    <other_name>glatiramer acetate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>mannitol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Previously diagnosed multiple sclerosis (MS, McDonald criteria 2005);&#xD;
&#xD;
          -  Disease more, than 1 year prior to inclusion;&#xD;
&#xD;
          -  Presence of 1 relapse previously OR at least 1 Gd+ lesion in T1 regimen;&#xD;
&#xD;
          -  EDSS 0-5,5;&#xD;
&#xD;
          -  Absence of exacerbations for 4 weeks prior to inclusion;&#xD;
&#xD;
          -  Readiness of patients (both genders) to use reliable methods of contraception (at&#xD;
             least 1 barrier method in combination with: spermicides, intrauterine device/oral&#xD;
             contraceptives)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary progressive and primary progressive forms of multiple sclerosis;&#xD;
&#xD;
          -  Other diseases (except multiple sclerosis), which may affect the assessment of the&#xD;
             severity of the symptoms of the underlying disease: mask, amplify, modify the symptoms&#xD;
             of the underlying disease or cause the clinical manifestations and changes in the data&#xD;
             of laboratory and instrumental methods of investigation similar to those of multiple&#xD;
             sclerosis;&#xD;
&#xD;
          -  Any acute or chronic infection in the acute stage;&#xD;
&#xD;
          -  Verified HIV, hepatitis B and C, syphilis;&#xD;
&#xD;
          -  Metabolic abnormalities (disorders), which manifest themselves as:&#xD;
&#xD;
               1. raising the general level of creatinine is more than 2 times over the upper limit&#xD;
                  of the normal range;&#xD;
&#xD;
               2. increase in transaminases (ALT, AST) or gamma-glutamyltransferase more than 2.5&#xD;
                  times over the upper limit of the normal range;&#xD;
&#xD;
          -  Violation of bone marrow function as reducing the total number of leukocytes &lt;3000&#xD;
             /mcl, or a platelet count &lt;125000 /mcl, hemoglobin concentration reduction, or &lt;100 g&#xD;
             / l;&#xD;
&#xD;
          -  EDSS&gt; 5,5 points;&#xD;
&#xD;
          -  Liver disease in the stage of decompensation;&#xD;
&#xD;
          -  Congestive heart failure, or not controlled by a drug therapy angina or arrhythmia;&#xD;
&#xD;
          -  Pregnancy, breast-feeding or planned pregnancy during the study period;&#xD;
&#xD;
          -  Use of any time prior to study any drug for modifying multiple sclerosis: interferon&#xD;
             beta-1a, interferon beta-1b, glatiramer acetate, azathioprine, corticosteroids and&#xD;
             immunomodulators (except for treating exacerbations corticosteroids), drugs and&#xD;
             monoclonal antibodies, cytotoxic and / or immunosuppressive drugs, including, but not&#xD;
             limited to drugs: mitoxantrone, cyclophosphamide, cyclosporine, fingolimod,&#xD;
             cladribine; or total lymphoid irradiation system;&#xD;
&#xD;
          -  System (IV, oral) corticosteroids within 30 days prior to the screening visit;&#xD;
&#xD;
          -  Intolerance or allergy to glatiramer acetate, mannitol or other components of the&#xD;
             BCD-063 preparations or Copaxone®-Teva;&#xD;
&#xD;
          -  History of drug addiction, alcoholism and abuse of drugs;&#xD;
&#xD;
          -  Contraindications to MRI (gadolinium allergic to or intolerant of closed spaces, any&#xD;
             renal failure, which may interfere with the removal of gadolinium - an acute or&#xD;
             chronic renal failure);&#xD;
&#xD;
          -  Any malignancies, including in anamnesis;&#xD;
&#xD;
          -  Vaccination within 4 weeks prior to study entry (prior to randomization);&#xD;
&#xD;
          -  Participation in any other clinical trial within 30 days prior to screening or&#xD;
             simultaneous participation in other clinical trials;&#xD;
&#xD;
          -  Previous participation in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roman A. Ivanov, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Biocad</affiliation>
  </overall_official>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>April 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2016</study_first_posted>
  <last_update_submitted>September 8, 2021</last_update_submitted>
  <last_update_submitted_qc>September 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Equivalence</keyword>
  <keyword>BCD-063</keyword>
  <keyword>Copaxone-Teva</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glatiramer Acetate</mesh_term>
    <mesh_term>Mannitol</mesh_term>
    <mesh_term>(T,G)-A-L</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

